Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2019-10-01 Sale | 2019-10-02 4:21 pm | Dova Pharmaceuticals Inc. | DOVA | ZACCARDELLI DAVID President & CEO | 5,275 | $27.9 | $147,173 | 76,647 (Direct) | View |
| 2019-09-30 Sale | 2019-10-02 4:21 pm | Dova Pharmaceuticals Inc. | DOVA | ALLEN LEE F MD PhD Chief Medical Officer | 978 | $28 | $27,384 | 9,635 (Direct) | View |
| 2019-09-30 Sale | 2019-10-02 4:20 pm | Dova Pharmaceuticals Inc. | DOVA | Hahn Mark W Chief Financial Officer | 775 | $28 | $21,700 | 9,024 (Direct) | View |
| 2019-09-30 Sale | 2019-10-02 4:20 pm | Dova Pharmaceuticals Inc. | DOVA | Hoitt Jason Chief Commercial Officer | 2,387 | $28 | $66,836 | 9,970 (Direct) | View |
| 2019-09-30 Sale | 2019-10-02 4:20 pm | Dova Pharmaceuticals Inc. | DOVA | Laliberte Kevin Sr. VP, Product Development | 3,696 | $28 | $103,488 | 4,761 (Direct) | View |
| 2019-09-25 Sale | 2019-09-27 4:05 pm | Dova Pharmaceuticals Inc. | DOVA | Laliberte Kevin Sr. VP, Product Development | 3,100 | $20 | $62,000 | 8,457 (Direct) | View |
| 2019-08-09 Purchase | 2019-08-12 4:15 pm | Dova Pharmaceuticals Inc. | DOVA | Manning Paul B Director 10% Owner | 28,062 | $15.87 | $445,344 | 14,762,242 (Indirect Direct) | View |
| 2019-07-31 Sale | 2019-08-01 4:31 pm | Dova Pharmaceuticals Inc. | DOVA | Laliberte Kevin Sr. VP, Product Development | 1,389 | $15.97 | $22,182 | 21,557 (Direct) | View |
| 2019-07-15 Sale | 2019-07-16 4:29 pm | Dova Pharmaceuticals Inc. | DOVA | Hoitt Jason Chief Commercial Officer | 7,580 | $15.26 | $115,664 | 12,357 (Direct) | View |
| 2019-07-09 Purchase | 2019-07-11 8:31 pm | Dova Pharmaceuticals Inc. | DOVA | PERCEPTIVE ADVISORS LLC PERCEPTIVE LIFE SCIENCES MASTER FUND LTD EDELMAN JOSEPH 10% Owner | 85,104 | $16.68 | $1,419,612 | 3,708,705 (Indirect) | View |
| 2019-07-05 Purchase | 2019-07-09 7:43 pm | Dova Pharmaceuticals Inc. | DOVA | PERCEPTIVE ADVISORS LLC PERCEPTIVE LIFE SCIENCES MASTER FUND LTD EDELMAN JOSEPH 10% Owner | 50,000 | $16.46 | $823,000 | 3,632,601 (Indirect) | View |
| 2019-07-01 Purchase | 2019-07-03 8:28 pm | Dova Pharmaceuticals Inc. | DOVA | PERCEPTIVE ADVISORS LLC PERCEPTIVE LIFE SCIENCES MASTER FUND LTD EDELMAN JOSEPH 10% Owner | 20,541 | $14.51 | $298,005 | 3,573,601 (Indirect) | View |
| 2019-07-02 Sale | 2019-07-03 4:24 pm | Dova Pharmaceuticals Inc. | DOVA | ZACCARDELLI DAVID President & CEO | 10,450 | $15.94 | $166,608 | 81,922 (Direct) | View |
| 2019-07-01 Sale | 2019-07-02 4:59 pm | Dova Pharmaceuticals Inc. | DOVA | Hahn Mark W Chief Financial Officer | 1,545 | $14.17 | $21,893 | 9,799 (Direct) | View |
| 2019-07-01 Sale | 2019-07-02 4:58 pm | Dova Pharmaceuticals Inc. | DOVA | JEFFS ROGER Director | 1,308 | $14.17 | $18,534 | 66,993 (Direct) | View |
| 2019-07-01 Sale | 2019-07-02 4:57 pm | Dova Pharmaceuticals Inc. | DOVA | Laliberte Kevin Sr. VP, Product Development | 1,191 | $14.17 | $16,876 | 12,946 (Direct) | View |
| 2019-07-01 Sale | 2019-07-02 4:56 pm | Dova Pharmaceuticals Inc. | DOVA | ALLEN LEE F MD PhD Chief Medical Officer | 1,957 | $14.19 | $27,770 | 10,613 (Direct) | View |
| 2019-06-28 Sale | 2019-07-02 4:55 pm | Dova Pharmaceuticals Inc. | DOVA | Hoitt Jason Chief Commercial Officer | 2,387 | $13.81 | $32,963 | 19,937 (Direct) | View |
| 2019-06-27 Purchase | 2019-07-01 7:23 pm | Dova Pharmaceuticals Inc. | DOVA | PERCEPTIVE ADVISORS LLC PERCEPTIVE LIFE SCIENCES MASTER FUND LTD EDELMAN JOSEPH 10% Owner | 427,209 | $13.35 | $5,703,209 | 3,553,060 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2019-11-12 Other | 2019-11-15 8:02 pm | N/A N/A | Dova Pharmaceuticals Inc. | DOVA | PERCEPTIVE ADVISORS LLC PERCEPTIVE LIFE SCIENCES MASTER FUND LTD EDELMAN JOSEPH 10% Owner | 3,125,851 | $0 | 3,125,851 (Indirect) | View |
| 2019-11-12 Disposition | 2019-11-12 4:42 pm | N/A 2018-12-18 | Dova Pharmaceuticals Inc. | DOVA | ZACCARDELLI DAVID President & CEO | 1,076,647 | $0 | 0 (Direct) | View |
| 2019-11-12 Disposition | 2019-11-12 4:41 pm | N/A 2029-04-25 | Dova Pharmaceuticals Inc. | DOVA | Wysenski Nancy Director | 16,274 | $0 | 0 (Direct) | View |
| 2019-11-12 Equity Swap | 2019-11-12 4:40 pm | N/A N/A | Dova Pharmaceuticals Inc. | DOVA | Stalfort Sean Director | 635,665 | $27.5 | 0 (Direct) | View |
| 2019-11-12 Disposition | 2019-11-12 4:39 pm | N/A 2027-05-24 | Dova Pharmaceuticals Inc. | DOVA | Novak Alfred J Director | 49,901 | $0 | 0 (Direct) | View |
| 2019-11-12 Equity Swap | 2019-11-12 4:38 pm | N/A N/A | Dova Pharmaceuticals Inc. | DOVA | Manning Paul B Director 10% Owner | 14,762,242 | $27.5 | 0 (Direct) | View |
| 2019-11-12 Disposition | 2019-11-12 4:37 pm | N/A 2027-03-27 | Dova Pharmaceuticals Inc. | DOVA | Laliberte Kevin Sr. VP, Product Development | 205,011 | $0 | 0 (Direct) | View |
| 2019-11-12 Disposition | 2019-11-12 4:36 pm | N/A 2027-05-24 | Dova Pharmaceuticals Inc. | DOVA | JEFFS ROGER Director | 109,993 | $0 | 0 (Direct) | View |
| 2019-11-12 Disposition | 2019-11-12 4:35 pm | N/A 2028-12-18 | Dova Pharmaceuticals Inc. | DOVA | Hoitt Jason Chief Commercial Officer | 259,970 | $0 | 0 (Direct) | View |
| 2019-11-12 Disposition | 2019-11-12 4:34 pm | N/A 2028-10-07 | Dova Pharmaceuticals Inc. | DOVA | Hahn Mark W Chief Financial Officer | 309,024 | $0 | 0 (Direct) | View |
| 2019-11-12 Disposition | 2019-11-12 4:33 pm | N/A 2027-05-24 | Dova Pharmaceuticals Inc. | DOVA | Goldman Steven M. Director | 167,696 | $0 | 0 (Direct) | View |
| 2019-11-12 Disposition | 2019-11-12 4:32 pm | N/A 2027-04-13 | Dova Pharmaceuticals Inc. | DOVA | ALLEN LEE F MD PhD Chief Medical Officer | 271,101 | $0 | 0 (Direct) | View |
| 2019-07-30 Option Award | 2019-08-01 4:31 pm | N/A 2029-07-30 | Dova Pharmaceuticals Inc. | DOVA | Laliberte Kevin Sr. VP, Product Development | 10,000 | $0 | 21,557 (Direct) | View |
| 2019-07-30 Option Award | 2019-08-01 4:30 pm | N/A 2029-07-30 | Dova Pharmaceuticals Inc. | DOVA | ALLEN LEE F MD PhD Chief Medical Officer | 10,000 | $0 | 10,000 (Direct) | View |
| 2019-06-26 Exercise | 2019-06-27 4:21 pm | N/A N/A | Dova Pharmaceuticals Inc. | DOVA | Goldman Steven M. Director | 916 | $7.32 | 167,597 (Direct) | View |
| 2019-06-26 Exercise | 2019-06-27 4:21 pm | N/A 2027-05-24 | Dova Pharmaceuticals Inc. | DOVA | Goldman Steven M. Director | 1,750 | $0 | 167,597 (Direct) | View |
| 2019-06-26 Exercise | 2019-06-27 4:21 pm | N/A N/A | Dova Pharmaceuticals Inc. | DOVA | Goldman Steven M. Director | 834 | $9.36 | 167,597 (Direct) | View |
| 2019-06-20 Exercise | 2019-06-24 4:54 pm | N/A N/A | Dova Pharmaceuticals Inc. | DOVA | Goldman Steven M. Director | 917 | $7.32 | 167,697 (Direct) | View |
| 2019-06-20 Exercise | 2019-06-24 4:54 pm | N/A 2027-05-24 | Dova Pharmaceuticals Inc. | DOVA | Goldman Steven M. Director | 1,750 | $0 | 167,697 (Direct) | View |
| 2019-06-20 Exercise | 2019-06-24 4:54 pm | N/A N/A | Dova Pharmaceuticals Inc. | DOVA | Goldman Steven M. Director | 833 | $9.36 | 167,697 (Direct) | View |
| 2019-04-26 Option Award | 2019-04-30 4:35 pm | N/A 2029-04-25 | Dova Pharmaceuticals Inc. | DOVA | Goldman Steven M. Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2019-04-26 Option Award | 2019-04-30 4:34 pm | N/A 2029-04-25 | Dova Pharmaceuticals Inc. | DOVA | JEFFS ROGER Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2019-04-26 Option Award | 2019-04-30 4:33 pm | N/A 2029-04-25 | Dova Pharmaceuticals Inc. | DOVA | Novak Alfred J Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2019-04-26 Option Award | 2019-04-30 4:33 pm | N/A 2029-04-25 | Dova Pharmaceuticals Inc. | DOVA | Wysenski Nancy Director | 10,000 | $0 | 10,000 (Direct) | View |